NO20054769L - Substituerte fenylalkansyrer - Google Patents
Substituerte fenylalkansyrerInfo
- Publication number
- NO20054769L NO20054769L NO20054769A NO20054769A NO20054769L NO 20054769 L NO20054769 L NO 20054769L NO 20054769 A NO20054769 A NO 20054769A NO 20054769 A NO20054769 A NO 20054769A NO 20054769 L NO20054769 L NO 20054769L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- useful
- ptp
- treatment
- phenylalkanoic acids
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 2
- 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Fats And Perfumes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Den foreliggende oppfinnelse er relatert til blandinger og farmasøytisk akseptable salter av formel (I): som er nyttige i behandling av metabolske forstyrrelser relatert til insulinresistanse eller hyperglycemi. Disse blandingene inkluderer inhibitorer av protein tyrosin fosfatase (PTP-1B) som er nyttige i behandling av diabetes og andre PTP-1B-medierte sykdommer, som cancer, nevrodegenrative sykdommer og lignende. Blandingene av oppfinnelsen er også. nyttige i farmasøytiske komposisjoner og metoder for behandling av de nevnte tilstandene.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46310203P | 2003-04-14 | 2003-04-14 | |
PCT/US2004/011650 WO2004092146A2 (en) | 2003-04-14 | 2004-04-14 | N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054769D0 NO20054769D0 (no) | 2005-10-17 |
NO20054769L true NO20054769L (no) | 2006-01-03 |
Family
ID=33300037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054769A NO20054769L (no) | 2003-04-14 | 2005-10-17 | Substituerte fenylalkansyrer |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040248937A1 (no) |
EP (1) | EP1633354B1 (no) |
JP (1) | JP2006524248A (no) |
KR (1) | KR20050121732A (no) |
CN (1) | CN1794989A (no) |
AT (1) | ATE384526T1 (no) |
AU (1) | AU2004231106A1 (no) |
BR (1) | BRPI0409447A (no) |
CA (1) | CA2522080A1 (no) |
DE (1) | DE602004011511T2 (no) |
EA (1) | EA200501607A1 (no) |
MX (1) | MXPA05010937A (no) |
NO (1) | NO20054769L (no) |
WO (1) | WO2004092146A2 (no) |
ZA (1) | ZA200509123B (no) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004210127B2 (en) | 2003-01-27 | 2009-10-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
EP1620420A2 (en) | 2003-04-30 | 2006-02-01 | The Institutes for Pharmaceutical Discovery, LLC | Substituted carboxylic acids |
EP1700856B1 (en) * | 2003-12-26 | 2015-11-11 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivative |
PT1756064E (pt) * | 2004-06-04 | 2008-07-22 | Merck & Co Inc | Derivados de pirazole, composições contendo tais compostos e métodos de utilização |
JP2008507528A (ja) | 2004-07-22 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 置換ピラゾール、このような化合物を含有する組成物及び使用方法 |
EP1805136A1 (en) * | 2004-10-28 | 2007-07-11 | The Institutes for Pharmaceutical Discovery, LLC | Substituted phenylalkanoic acids |
AU2006276072A1 (en) | 2005-07-26 | 2007-02-08 | Merck Sharp & Dohme Corp. | Process for synthesizing a substituted pyrazole |
DE102006013957A1 (de) * | 2006-03-27 | 2007-10-04 | Bayer Healthcare Aktiengesellschaft | Substituierte N-Benzyl-N-phenylbenzolsulfonamide |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
GB0815782D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
GB0815784D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
MX2013006768A (es) | 2010-12-23 | 2013-07-22 | Pfizer | Moduladores de receptor de glucagon. |
WO2012100734A1 (en) * | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
EA023517B1 (ru) | 2011-02-08 | 2016-06-30 | Пфайзер Инк. | Модуляторы глюкагонового рецептора |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US8927577B2 (en) | 2011-07-22 | 2015-01-06 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
KR20150087400A (ko) | 2012-11-20 | 2015-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물 |
CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3126339A1 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
CA2944614A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases |
JP2017511319A (ja) | 2014-04-03 | 2017-04-20 | バイエル ファーマ アクチエンゲゼルシャフト | キラル2,5−ジ置換されたシクロペンタンカルボン酸誘導体およびそれの使用 |
WO2017139414A1 (en) | 2016-02-09 | 2017-08-17 | Inventisbio Inc. | Inhibitor of indoleamine-2,3-dioxygenase (ido) |
CN106632076B (zh) * | 2016-09-20 | 2019-04-30 | 中国药科大学 | 4,6-二苯基嘧啶类化合物、其制备方法和医药用途 |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
KR102606541B1 (ko) * | 2021-04-23 | 2023-11-29 | 가천대학교 산학협력단 | 바이페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
CN115337301A (zh) * | 2022-07-22 | 2022-11-15 | 汕头大学医学院第一附属医院 | Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2284180T3 (es) * | 1996-01-23 | 2007-11-01 | SHIONOGI & CO., LTD. | Derivados de aminoacidos sulfonados e inhibidores de metaloproteinasas que contienen los mismos. |
PL195955B1 (pl) * | 1996-04-12 | 2007-11-30 | Searle & Co | Związek, pochodna benzenosulfonamidu, sposób jegowytwarzania, kompozycja farmaceutyczna zawierająca go oraz jego zastosowanie |
US6677364B2 (en) * | 1998-04-20 | 2004-01-13 | G.D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
IL127965A0 (en) * | 1996-07-19 | 1999-11-30 | Tularik Inc | Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same |
PE20000127A1 (es) * | 1997-12-22 | 2000-03-14 | Novartis Ag | Derivado de bencenosulfonamida |
EP1077960A1 (en) * | 1998-05-12 | 2001-02-28 | American Home Products Corporation | (2-acylaminothiazole-4-yl)acetic acid derivatives |
AU773273B2 (en) * | 1999-02-26 | 2004-05-20 | Bristol-Myers Squibb Company | Novel sulfonamide compounds and uses thereof |
ATE329920T1 (de) * | 1999-09-10 | 2006-07-15 | Novo Nordisk As | Modulatoren der protein tyrosin phosphatase (ptpases) |
AU782878B2 (en) * | 2000-02-05 | 2005-09-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
AU2001248765A1 (en) * | 2000-04-21 | 2001-11-12 | Shionogi And Co., Ltd. | Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders |
AU2001248820A1 (en) * | 2000-04-28 | 2001-11-12 | Shionogi And Co., Ltd. | Thiazole and oxazole derivatives |
WO2001083431A1 (fr) * | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Inhibiteurs de mmp-12 |
DE60128475T2 (de) * | 2000-07-25 | 2008-02-07 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
US6472545B2 (en) * | 2000-08-29 | 2002-10-29 | Abbott Laboratories | Protein tyrosine phosphatase inhibitors |
KR20030030036A (ko) * | 2000-09-29 | 2003-04-16 | 시오노기세이야쿠가부시키가이샤 | 티아졸 또는 옥사졸 유도체 |
JP2002114768A (ja) * | 2000-10-11 | 2002-04-16 | Japan Tobacco Inc | 2−(2,5−ジハロゲン−3,4−ジヒドロキシフェニル)アゾール化合物及びそれを含有してなる医薬組成物 |
DE60141156D1 (de) * | 2000-11-02 | 2010-03-11 | Ajinomoto Kk | Neue pyrazolderivate und diese enthaltende mittel gegen diabetes |
US7091230B2 (en) * | 2001-02-09 | 2006-08-15 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
DE10150172A1 (de) * | 2001-10-11 | 2003-04-30 | Morphochem Ag | Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren |
JP2005508355A (ja) * | 2001-10-19 | 2005-03-31 | トランス テック ファーマ,インコーポレイテッド | 治療薬としてのビス−ヘテロアリールアルカン |
JP4219810B2 (ja) * | 2001-10-26 | 2009-02-04 | 塩野義製薬株式会社 | Mmp阻害作用を有するスルホンアミド誘導体 |
AU2002356981A1 (en) * | 2001-11-19 | 2003-06-10 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
US7163952B2 (en) * | 2001-12-03 | 2007-01-16 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
JP4434744B2 (ja) * | 2002-01-30 | 2010-03-17 | アムジェン インコーポレイテッド | アリールスルホンアミドベンジル化合物 |
CA2493913A1 (en) * | 2002-07-30 | 2004-02-05 | Merck & Co., Inc. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
PT1537078E (pt) * | 2002-08-29 | 2010-06-18 | Merck Sharp & Dohme | Indoles que possuem actividade antidiabética |
-
2004
- 2004-04-14 BR BRPI0409447-6A patent/BRPI0409447A/pt not_active IP Right Cessation
- 2004-04-14 EA EA200501607A patent/EA200501607A1/ru unknown
- 2004-04-14 CA CA002522080A patent/CA2522080A1/en not_active Abandoned
- 2004-04-14 US US10/824,057 patent/US20040248937A1/en not_active Abandoned
- 2004-04-14 EP EP04750170A patent/EP1633354B1/en not_active Expired - Lifetime
- 2004-04-14 CN CNA2004800145768A patent/CN1794989A/zh active Pending
- 2004-04-14 DE DE602004011511T patent/DE602004011511T2/de not_active Expired - Fee Related
- 2004-04-14 WO PCT/US2004/011650 patent/WO2004092146A2/en active IP Right Grant
- 2004-04-14 MX MXPA05010937A patent/MXPA05010937A/es unknown
- 2004-04-14 KR KR1020057019661A patent/KR20050121732A/ko not_active Application Discontinuation
- 2004-04-14 JP JP2006510073A patent/JP2006524248A/ja active Pending
- 2004-04-14 AT AT04750170T patent/ATE384526T1/de not_active IP Right Cessation
- 2004-04-14 AU AU2004231106A patent/AU2004231106A1/en not_active Abandoned
-
2005
- 2005-10-17 NO NO20054769A patent/NO20054769L/no not_active Application Discontinuation
- 2005-11-11 ZA ZA200509123A patent/ZA200509123B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA05010937A (es) | 2005-11-25 |
US20040248937A1 (en) | 2004-12-09 |
KR20050121732A (ko) | 2005-12-27 |
DE602004011511D1 (de) | 2008-03-13 |
EP1633354B1 (en) | 2008-01-23 |
CA2522080A1 (en) | 2004-10-28 |
WO2004092146A2 (en) | 2004-10-28 |
EA200501607A1 (ru) | 2006-06-30 |
ATE384526T1 (de) | 2008-02-15 |
WO2004092146A3 (en) | 2004-12-29 |
CN1794989A (zh) | 2006-06-28 |
DE602004011511T2 (de) | 2009-01-29 |
ZA200509123B (en) | 2007-04-25 |
BRPI0409447A (pt) | 2006-04-18 |
EP1633354A2 (en) | 2006-03-15 |
NO20054769D0 (no) | 2005-10-17 |
AU2004231106A1 (en) | 2004-10-28 |
JP2006524248A (ja) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054769L (no) | Substituerte fenylalkansyrer | |
NO20054958L (no) | Substitulerte aminokarboksylsyrer | |
NO20054957L (no) | Subtituerte karboksylsyrer | |
NO20055129L (no) | Fenylsubstituerte karboksylsyrer | |
TW200630327A (en) | Substituted phenylalkanoic acids | |
ATE372324T1 (de) | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen | |
MXPA05011539A (es) | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. | |
TW200630354A (en) | Substituted amino carboxylic acids | |
WO2006055708A3 (en) | Heterocycle substituted carboxylic acids for the treatment of diabetes | |
EA200600414A1 (ru) | ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ) | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
DE602004017174D1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
NO20083572L (no) | Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer | |
WO2007089857A3 (en) | Substituted imidazole derivatives and their use as ptpase inhibitors | |
ATE432072T1 (de) | Verwendung von adapalen zur behandlung dermatologischer erkrankungen | |
BRPI0514448A (pt) | derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias | |
ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
WO2004071448A3 (en) | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases | |
TW200631949A (en) | Substituted carboxylic acids | |
ATE538796T1 (de) | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit | |
WO2006138589A3 (en) | Opioid receptor ligands | |
NO20061290L (no) | Nye forbindelser | |
ATE528299T1 (de) | Cyclische ketale als beta-sekretase-inhibitoren zur behandlung von alzheimer-krankheit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |